Rahul Y. Pagar
Department of Pharmaceutics, K.B.H.S.S. Trust’s Institute of Pharmacy (Affiliated to Savitribai Phule Pune University, Pune), Malegaon, Nashik, Maharashtra, India, 423105

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Development and optimization of amorphous dry powder formulation of bilastine for pulmonary delivery using lyophilization technique Sheetal Z. Godse; Avinash B. Gangurde; Rahul Y. Pagar
Journal of Applied Pharmaceutical Research Vol. 14 No. 5 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i5.2594

Abstract

Background: Conventional treatments for pulmonary diseases like asthma and chronic obstructive pulmonary disease (COPD) often lack rapid, targeted action. To address this, direct pulmonary drug delivery is preferred because it offers faster onset, greater efficacy, and fewer systemic side effects. Dry Powder Inhalers (DPIs) have emerged as the optimal choice because they are stable, portable, easy to use, and propellant-free. Methodology: We prepared bilastine DPIs by lyophilization from an ethanol:water solution containing Soluplus (20-30% w/w), mannitol (30-40% w/w), and L-leucine (5-15% w/w) as key excipients. We employed a Box-Behnken experimental design with 17 formulations to systematically optimize fine particle fraction, mass median aerodynamic diameter, and amorphicity index. We performed XRD, SEM, FTIR, DSC, flow characterization, and aerodynamic performance assessment using the Next Generation Impactor. We used goat pulmonary tissue in ex vivo diffusion studies. Results and Discussion: The F12 batch was optimal because it had a higher FPF (44.1%), good flow characteristics (Carr's index: 12.8%), an optimal MMAD (3.86 µm), and a suitable amorphicity index (0.65). Ex vivo research showed cumulative diffusion of 86.2%, compared with 22.6% for crystalline drugs. Conclusion: The optimized amorphous bilastine dry powder inhaler (DPI) demonstrated improved aerodynamic performance and pulmonary drug delivery. We attribute enhanced ex vivo drug diffusion to reduced particle size, improved surface properties, increased dispersibility, and efficient carrier-assisted deposition. These characteristics contributed to greater fine particle generation and enhanced pulmonary permeation. The findings suggest that the lyophilization-based amorphous formulation is a promising strategy for improving pulmonary drug delivery. However, further in vivo studies are required to confirm its therapeutic efficacy and clinical potential.